Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 226.00 |
Gross Profit | 0.00 | -537.00K | -466.00K | -129.00K | -4.77K |
EBITDA | -48.99M | -66.33M | -62.84M | -35.70M | -8.32M |
Net Income | -49.59M | -66.86M | -58.62M | -35.53M | -8.28M |
Balance Sheet | |||||
Total Assets | 252.09M | 289.64M | 341.14M | 390.56M | 36.52M |
Cash, Cash Equivalents and Short-Term Investments | 245.48M | 281.80M | 330.39M | 384.06M | 36.09M |
Total Debt | 2.33M | 3.05M | 3.69M | 3.63M | 0.00 |
Total Liabilities | 10.00M | 11.96M | 13.83M | 8.43M | 47.83M |
Stockholders Equity | 242.10M | 277.69M | 327.31M | 382.13M | -11.31M |
Cash Flow | |||||
Free Cash Flow | -43.45M | -58.82M | -52.23M | -30.91M | -8.74M |
Operating Cash Flow | -43.10M | -58.56M | -51.32M | -29.38M | -8.67M |
Investing Cash Flow | 43.95M | 52.54M | -220.99M | -53.64M | -33.56M |
Financing Cash Flow | 513.00K | 724.00K | 235.00 | 379.21K | 44.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $360.65M | ― | 322.49% | ― | -30.66% | 36.48% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
47 Neutral | $229.35M | ― | -22.59% | ― | ― | 26.63% | |
46 Neutral | $213.56M | ― | -32.97% | ― | ― | ― | |
45 Neutral | $531.89M | ― | -32.12% | ― | ― | 10.98% | |
38 Underperform | $279.77M | ― | -66.13% | ― | ― | 43.21% | |
34 Underperform | $325.32M | ― | -34.97% | ― | ― | -140.77% |
Design Therapeutics, Inc. has updated its corporate presentation to be used in meetings with investors, analysts, and others, which has been attached to a Current Report on Form 8-K. This update, although furnished for informational purposes, is not deemed filed under the Securities Exchange Act or the Securities Act, thus limiting its formal legal implications.